Jason Rhodes Sells 195,427 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 195,427 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $4,131,326.78. Following the completion of the sale, the director directly owned 975,931 shares of the company’s stock, valued at approximately $20,631,181.34. This represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Down 1.9%

Shares of NASDAQ DYN opened at $21.79 on Thursday. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The business has a 50-day moving average price of $18.55 and a two-hundred day moving average price of $18.13. The firm has a market capitalization of $3.60 billion, a PE ratio of -6.77 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) earnings per share. As a group, analysts predict that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on DYN. TD Cowen started coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Chardan Capital reiterated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Finally, Sanford C. Bernstein boosted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. increased its position in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 14.9% in the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock worth $219,376,000 after buying an additional 1,455,151 shares during the last quarter. State Street Corp lifted its position in shares of Dyne Therapeutics by 27.0% in the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock worth $130,910,000 after buying an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock worth $101,164,000 after acquiring an additional 1,618,000 shares in the last quarter. Finally, Orbis Allan Gray Ltd bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $93,926,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.